Merck KGaA Profit Beats Estimates on Cost-Cutting

May 14 (Bloomberg) -- Merck KGaA, the German maker of cancer drug Erbitux, said first-quarter profit rose on higher-than-expected savings from a reorganization program, and forecast it will achieve 2014 targets a year ahead of schedule. Mark Barton reports on Bloomberg Television's "Countdown." (Source: Bloomberg)

The Challenges Facing Central Banks
52:24 - Columbia Threadneedle EMEA CIO and Global Head of Equities Mark Burgess discusses the outlook for the Fed and the ECB with Mark Barton on "Bloomberg Surveillance."
  • Turnill: London Brexit Headwinds Larger Than Rest of U.K.
  • Wood: A Whole Load of Bad News to Come for U.K. Economy
  • Turnill: Long-Term European Bank Headwinds Still Strong